chr19-41012316-T-C
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_StrongBA1
The ENST00000324071.10(CYP2B6):c.983T>C(p.Ile328Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00364 in 1,614,058 control chromosomes in the GnomAD database, including 196 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely benignin UniProt.
Frequency
Consequence
ENST00000324071.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP2B6 | NM_000767.5 | c.983T>C | p.Ile328Thr | missense_variant | 7/9 | ENST00000324071.10 | NP_000758.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CYP2B6 | ENST00000324071.10 | c.983T>C | p.Ile328Thr | missense_variant | 7/9 | 1 | NM_000767.5 | ENSP00000324648 | P1 | |
CYP2B6 | ENST00000597612.1 | n.478T>C | non_coding_transcript_exon_variant | 2/3 | 1 | |||||
CYP2B6 | ENST00000593831.1 | c.275T>C | p.Ile92Thr | missense_variant | 3/5 | 2 | ENSP00000470582 | |||
CYP2B6 | ENST00000598834.2 | c.*424T>C | 3_prime_UTR_variant, NMD_transcript_variant | 8/10 | 5 | ENSP00000496294 |
Frequencies
GnomAD3 genomes AF: 0.0203 AC: 3085AN: 152082Hom.: 110 Cov.: 32
GnomAD3 exomes AF: 0.00508 AC: 1277AN: 251302Hom.: 54 AF XY: 0.00355 AC XY: 482AN XY: 135840
GnomAD4 exome AF: 0.00191 AC: 2791AN: 1461858Hom.: 85 Cov.: 32 AF XY: 0.00165 AC XY: 1202AN XY: 727236
GnomAD4 genome AF: 0.0203 AC: 3090AN: 152200Hom.: 111 Cov.: 32 AF XY: 0.0194 AC XY: 1447AN XY: 74420
ClinVar
Submissions by phenotype
CYP2B6-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 02, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
nevirapine response - Toxicity Other:1
drug response, reviewed by expert panel | curation | PharmGKB | Mar 24, 2021 | PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications. Drug-variant association: Toxicity |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at